TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06544265: SynKIR-310 for Relapsed/Refractory B-NHL

Sponsor: Verismo Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$848,232

Rescue Site Savings

+$565,488

Unlock Full NCT06544265 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06544265 Rescue Dossier →